RCUS · Biotech · NYSE · As of 21 Nov 2026
Arcus Biosciences, Inc. stock: filings, catalysts and timeline
Sign in to follow
AIR Score
Cautious · 46 / 100
AIR confidence
Support behind the full AIR read.
What is this? →Hide
How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.
The Discovery Gap
High
Gap confidence
How fully AIR could measure this Gap — separate from the AIR Score's confidence.
What is this? →Hide
How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.
Five perspectives
FundamentalsWhat is this?HideToo few of the required measures on file
How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.
Source: SEC XBRL financial statements.
ValueWhat is this?HideToo few of the required measures on file
How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.
Source: SEC XBRL financial statements and end-of-day prices.
News flowWhat is this?HideBalanced
What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.
Source: SEC EDGAR 8-K filings and FDA approvals.
MomentumWhat is this?HideWatch
The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.
Source: End-of-day prices.
SafetyWhat is this?HideBalanced
The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.
Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.
Rating words, not raw numbers.
Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on News flow, Momentum and Safety, and the missing score lowers its AIR confidence.
Discovery Gap: High (30/100) · Gap confidence 55/100
Discovery gap
Filings show more traction than the tape reflects.
Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.
What is this?Hide
How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.
Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.
How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.
This month at a glance
Evidence timeline
What changed — last 90 days
As of 15 Nov 2026The company reported preliminary cash, cash equivalents, and marketable securities of approximately $694.0 million as of September 30, 2026, unaudited and subject to completion of financial closing procedures.
Results · 8-K filed 21 Oct →
The company reported Phase 3 progress for casdatifan across kidney cancer lines, with PEAK-1 enrollment nearing completion and PEAK-20 initiating by year-end.
Results · 8-K filed 4 Nov →
The company filed its quarterly report for the period ending September 30, 2026.
Quarterly/annual report · 10-Q filed 4 Nov →
What the company disclosed, not verified by AIR · sources link to the Evidence timeline below.
- Expected
Thu 25 Feb · expected 10-K
Last year filed 25 Feb 2026.
Wed 5 May · expected 10-Q
Last year filed 5 May 2026.
- Filed
Wed 4 Nov · 8-K
8-K · Item 2.02 — Results of operations
Arcus reported positive Phase 3 progress for casdatifan across kidney cancer lines. PEAK-1 enrollment nearing completion; PEAK-20 initiating by year-end. ARC-20 data showed strong efficacy benchmarks. Cash position of $694M plus $288M equity raise supports runway into 2029.
Gap High · 25 → High · 33Progress is running ahead of attention.
Wed 4 Nov · 10-Q
Quarterly report (10-Q), period ending 30 Sep 2026
Gap High · 25 → High · 33Progress is running ahead of attention.
Fri 23 Oct · 8-K
Wed 21 Oct · 8-K
8-K · Item 2.02 — Results of operations
Arcus reports preliminary cash, cash equivalents, and marketable securities of approximately $694.0 million as of September 30, 2026. Figure is unaudited, subject to completion of financial closing procedures, and may vary from actual position.
Gap Medium · 18 → High · 27Progress is running ahead of attention.
The price trend weakened.
Tue 20 Oct · 8-K
8-K · Item 8.01 — Other events
Gap Medium · 18 → High · 29Progress is running ahead of attention.
The price trend weakened.
Wed 5 Aug · 8-K
Wed 5 Aug · 10-Q
Quarterly report (10-Q), period ending 30 Jun 2026
Fri 12 Jun · 8-K
Tue 5 May · 8-K
Tue 5 May · 10-Q
Quarterly report (10-Q), period ending 31 Mar 2026
Mon 20 Apr · 8-K
Mon 23 Mar · 8-K
Wed 25 Feb · 8-K
Wed 25 Feb · 10-K
Annual report (10-K), FY2025
Thu 18 Dec · 8-K
Fri 12 Dec · 8-K
Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.
Ask AIR
What would change our view
Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.